同药同价？特朗普将强制要求美国药品价格与最低价格国家相同，称“美国药品价格可能下降30%至80%”

Core Viewpoint - Trump plans to sign an executive order mandating that U.S. prescription drug prices align with the lowest prices in other countries, potentially leading to a price drop of 30% to 80% for U.S. drugs, while global prices may rise to achieve balance [1][2] Group 1: Policy Implications - The executive order aims to significantly reduce healthcare costs in the U.S., challenging the pharmaceutical industry's claim that high prices are necessary for innovation and research [2][4] - The specifics of the executive order, including its applicability to government programs and specific drug categories, remain unclear [1][4] Group 2: Historical Context - This is not Trump's first attempt to reform drug pricing; during his first term, he proposed a Medicare pilot program to align prices with those in countries like France and Japan, which was ultimately overturned in court [3][4] - The Biden administration has since pursued legislative measures, including the Inflation Reduction Act, which allows for price negotiations for high-cost drugs under Medicare [4] Group 3: Market Reactions - Following the announcement, Japan's pharmaceutical index dropped by 3.9%, indicating immediate market reactions to the potential policy changes [1]